abatacept infusion — Competitive Intelligence Brief

abatacept infusion (abatacept infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: T-cell costimulation inhibitor. Area: Immunology.

marketed T-cell costimulation inhibitor CD80/CD86 Immunology Small molecule

Target snapshot

abatacept infusion (abatacept infusion) — University of Minnesota. Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
abatacept infusion TARGET	abatacept infusion	University of Minnesota	marketed	T-cell costimulation inhibitor	CD80/CD86
abatacept (ABA)	abatacept (ABA)	Bristol-Myers Squibb	marketed	CTLA-4 immunoglobulin fusion protein	CD80/CD86
IV Abatacept	IV Abatacept	Rüdiger B. Müller	marketed	T-cell costimulation inhibitor	CD80/CD86
ABT	ABT	Shanghai Public Health Clinical Center	marketed	CTLA-4 modulator	CD80/CD86
Abatacept plus	Abatacept plus	Massachusetts General Hospital	phase 3	T-cell costimulation modulator	CD80/CD86
Belatacept MI (more intensive)	Belatacept MI (more intensive)	Bristol-Myers Squibb	phase 3	T-cell costimulation blocker	CD80/CD86 (via CTLA4-Ig fusion protein)
Belatacept LI (less intensive)	Belatacept LI (less intensive)	Bristol-Myers Squibb	phase 3	T-cell costimulation blocker	CD80/CD86 (via CTLA4-Ig fusion protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (T-cell costimulation inhibitor class)

1. Bristol-Myers Squibb · 1 drug in this class
2. Rüdiger B. Müller · 1 drug in this class
3. University Hospital, Montpellier · 1 drug in this class
4. University of Minnesota · 1 drug in this class